Previous close | 838.10 |
Open | 830.10 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 829.80 - 841.10 |
52-week range | 388.20 - 841.10 |
Volume | |
Avg. volume | 14 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 08 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Automated pumps are already used by about 40% of those with the autoimmune version of diabetes, known as Type-1.
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Assuming the rosier expectations will positively unfold, a reality check is done to compare the current valuation to informative financial ratios